Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peposertib and Tuvusertib in Advanced Solid Tumors
NCT05687136Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of peposertib and tuvusertib in solid tumor, sponsored by National Cancer Institute. Primary endpoints: Incidence of dose limiting toxicity up to 28 days and Incidence of adverse events. Started Jun 2024; status: recruiting.
02
Drugs
peposertibtuvusertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05687136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05687136.